HSIC · Henry Schein Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $577M | first half of 2026 | — |
|
|
|||
| Internal sales growth non-GAAP | 0.7% | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HSIC
this stock
Henry Schein Inc
|
$9.95B | +18.1% | +5.9% | 26.0 | 5.7% |
|
MCK
Mckesson Corp
|
$100.26B | +4.1% | +3.1% | 23.1 | 3.1% |
|
COR
Cencora, Inc.
|
$60.49B | -6.1% | +9.3% | 23.5 | 2.7% |
|
CAH
Cardinal Health Inc
|
$54.65B | +14.3% | +14.2% | — | 2.8% |
|
EBOSY
EBOS Group Limited/ADR
|
$2.67B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HSIC | -1.6% | +5.3% | +9.6% | +4.1% | +18.1% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -1.2% | +2.4% | -2.0% | +1.2% | +5.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.